Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 9 of 46

DMARDs Included in the Comparative Effectiveness Review

The nonbiologic and biologic DMARDs that have been studied in children with JIA and were included in the CER are listed by name; the target of action for each DMARD, as currently understood, is given.

Nonbiologic DMARDs include:
Azathioprine:  Target of activity is purine synthesis; inhibits T-lymphocyte proliferation.
D-Penicillamine: Target of activity is unknown.
Hydroxychloroquine: Target of activity is uncertain but likely is T-lymphocytes.
Leflunomide:  Target of activity is pyridine synthesis.
Methotrexate: Target of activity is dihydrofolate reductase and folate metabolism.
Sulfasalazine: Target of activity is uncertain but likely multifactorial, including impairment of lymphocyte function and cytokine synthesis.

Biologic DMARDs include:
Adalimumab: Target of activity is TNF-α.
Etanercept: Target of activity is TNF-α.
Infliximab: Target of activity is TNF-α.
Abatacept: Target of activity is CD28.
Anakinra: Target of activity is interleukin 1 (IL-1). 
Rituximab: Target of activity is CD20.
Tocilizumab: Target of activity is the IL-6 receptor.
Intravenous immunoglobulin: Target of activity is Fc receptors.